New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.62
0.17
+0.10%
Follow AZN
Alert me
Revenue to profit Fiscal 2025, year to Dec 31, 2025
Of every $100 of revenue, $21.11 was left as profit. What is an income statement?
| Revenue | 58.7 | 100.0% |
|---|---|---|
| Cost of revenue | −10.6 | −18.1% |
| Gross profit | 48.1 | 81.9% |
| Research & development | −14.2 | −24.2% |
| Selling, general & admin | −20.5 | −34.9% |
| Other operating costs | +0.4 | 0.6% |
| Operating income | 13.7 | 23.4% |
| Other income, net | −1.3 | −2.3% |
| Income tax | −2.2 | −3.7% |
| Other items | +2.2 | 3.7% |
| Net income | 12.4 | 21.1% |
Net margin (right axis)
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.0B | $22.5B | $22.1B | $24.4B | $26.6B | $37.4B | $44.4B | $45.8B | $54.1B | $58.7B |
| Operating income | $4.9B | $3.7B | $3.4B | $2.9B | $5.2B | $1.1B | $3.8B | $8.2B | $10.0B | $13.7B |
| Net income | $3.6B | $2.2B | $2.0B | $1.5B | $3.9B | −$265M | $2.5B | $6.9B | $8.7B | $12.4B |
| Net margin (right axis) | 15.4% | 9.9% | 9.0% | 6.3% | 14.7% | −0.7% | 5.6% | 15.1% | 16.1% | 21.1% |
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
58,739.00 | 54,073.00 | 45,811.00 | 44,351.00 | 37,417.00 | 26,617.00 | 24,384.00 | 22,090.00 | 22,465.00 | 23,002.00 |
Revenue Growth |
8.63% | 18.03% | 3.29% | 18.53% | 40.58% | 9.16% | 10.38% | (1.67%) | (2.33%) | (6.90%) |
Cost of Revenue |
10,633.00 | 10,207.00 | 8,268.00 | 12,391.00 | 12,437.00 | 5,299.00 | 4,921.00 | 4,936.00 | 4,318.00 | 4,126.00 |
Gross Profit |
48,106.00 | 43,866.00 | 37,543.00 | 31,960.00 | 24,980.00 | 21,318.00 | 19,463.00 | 17,154.00 | 18,147.00 | 18,876.00 |
R&D Expenses |
14,232.00 | 13,583.00 | 10,935.00 | 9,762.00 | 9,736.00 | 5,991.00 | 6,059.00 | 5,932.00 | 5,757.00 | 5,890.00 |
SG&A Expenses |
20,512.00 | 20,532.00 | 19,755.00 | 18,955.00 | 15,680.00 | 11,693.00 | 12,021.00 | 10,362.00 | 10,543.00 | 9,739.00 |
Operating Income |
13,743.00 | 10,003.00 | 8,193.00 | 3,757.00 | 1,056.00 | 5,162.00 | 2,924.00 | 3,387.00 | 3,677.00 | 4,902.00 |
Non-operating Income/Expense |
(1,341.00) | (1,312.00) | (1,294.00) | (1,256.00) | (1,321.00) | (1,246.00) | (1,376.00) | (1,394.00) | (1,450.00) | (1,350.00) |
Non-operating Interest Expenses |
1,694.00 | 1,742.00 | 1,626.00 | 1,346.00 | 1,300.00 | 1,306.00 | 1,432.00 | 1,419.00 | 1,508.00 | 1,384.00 |
| 12,402.00 | 8,691.00 | 6,899.00 | 2,501.00 | (265.00) | 3,916.00 | 1,548.00 | 1,993.00 | 2,227.00 | 3,552.00 | |
Income Tax Provision |
2,169.00 | 1,650.00 | 938.00 | (792.00) | (380.00) | 772.00 | 321.00 | (57.00) | (641.00) | 146.00 |
Income after Tax |
10,233.00 | 7,041.00 | 5,961.00 | 3,293.00 | 115.00 | 3,144.00 | 1,227.00 | 2,050.00 | 2,868.00 | 3,406.00 |
Non-Controlling Interest |
8.00 | 6.00 | 6.00 | 5.00 | 3.00 | (52.00) | (108.00) | (105.00) | (133.00) | (93.00) |
Net Income Common |
10,225.00 | 7,035.00 | 5,955.00 | 3,288.00 | 112.00 | 3,196.00 | 1,335.00 | 2,155.00 | 3,001.00 | 3,499.00 |
EPS (Basic) |
6.60 | 4.54 | 3.84 | 2.12 | 0.08 | 2.44 | 1.02 | 1.70 | 2.38 | 2.76 |
EPS (Diluted) |
6.55 | 4.50 | 3.82 | 2.12 | 0.08 | 2.44 | 1.02 | 1.70 | 2.38 | 2.76 |
Shares (Basic, Weighted) |
1,550.00 | 1,550.00 | 1,549.00 | 1,548.00 | 1,418.00 | 1,312.00 | 1,301.00 | 1,267.00 | 1,266.00 | 1,265.00 |
Shares (Diluted, Weighted) |
1,562.00 | 1,563.00 | 1,562.00 | 1,560.00 | 1,427.00 | 1,313.00 | 1,301.00 | 1,267.00 | 1,266.00 | 1,266.00 |
Gross Margin |
81.90% | 81.12% | 81.95% | 72.06% | 66.76% | 80.09% | 79.82% | 77.66% | 80.78% | 82.06% |
EBIT Margin |
23.40% | 18.50% | 17.88% | 8.47% | 2.82% | 19.39% | 11.99% | 15.33% | 16.37% | 21.31% |
EBT margin |
21.11% | 16.07% | 15.06% | 5.64% | (0.71%) | 14.71% | 6.35% | 9.02% | 9.91% | 15.44% |
Net Profit Margin |
17.41% | 13.01% | 13.00% | 7.41% | 0.30% | 12.01% | 5.47% | 9.76% | 13.36% | 15.21% |
Free Cash Flow Margin |
15.01% | 13.78% | 15.26% | 17.96% | 11.66% | 12.21% | 10.75% | 16.28% | 15.21% | 14.52% |
EBITDA |
19,476.00 | 16,691.00 | 13,580.00 | 9,237.00 | 7,586.00 | 8,311.00 | 6,686.00 | 7,140.00 | 6,713.00 | 7,259.00 |
EBIT |
13,743.00 | 10,003.00 | 8,193.00 | 3,757.00 | 1,056.00 | 5,162.00 | 2,924.00 | 3,387.00 | 3,677.00 | 4,902.00 |
Income from Continuous Operations |
10,233.00 | 7,041.00 | 5,961.00 | 3,293.00 | 115.00 | 3,144.00 | 1,227.00 | 2,050.00 | 2,868.00 | 3,406.00 |
Consolidated Net Income/Loss |
10,233.00 | 7,041.00 | 5,961.00 | 3,293.00 | 115.00 | 3,144.00 | 1,227.00 | 2,050.00 | 2,868.00 | 3,406.00 |
EPS (Basic, from Continuous Ops) |
3.30 | 2.27 | 3.85 | 2.13 | 0.08 | 2.40 | 0.94 | 1.62 | 2.27 | 2.69 |
EPS (Basic, Consolidated) |
3.30 | 2.27 | 3.85 | 2.13 | 0.08 | 2.40 | 0.94 | 1.62 | 2.27 | 2.69 |
EPS (Diluted, from Cont. Ops) |
3.28 | 2.25 | 3.82 | 2.11 | 0.08 | 2.39 | 0.94 | 1.62 | 2.27 | 2.69 |
Shares (Diluted, Average) |
1,562.00 | 1,563.00 | 1,562.00 | 1,560.00 | 1,427.00 | 1,313.00 | 1,301.00 | 1,267.00 | 1,267.00 | 1,266.00 |
EPS (Diluted, Consolidated) |
3.28 | 2.25 | 3.82 | 2.11 | 0.08 | 2.39 | 0.94 | 1.62 | 2.27 | 2.69 |
EBITDA Margin |
33.16% | 30.87% | 29.64% | 20.83% | 20.27% | 31.22% | 27.42% | 32.32% | 29.88% | 31.56% |
Operating Cash Flow Margin |
24.81% | 21.94% | 22.58% | 22.11% | 15.94% | 18.03% | 12.18% | 11.85% | 15.93% | 18.02% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026